Showing 1 - 3 results of 3 for search 'Glotz, D', query time: 0.02s
Refine Results
-
1
Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation by Naesens, M, Loupy, A, Hilbrands. L, Oberbauer, R, Bellini, MI, Glotz, D, Grinyó, J, Heemann, U, Jochmans, I, Pengel, L, Reinders, M, Schneeberger, S, Budde, K
Published 2022Journal article -
2
Proposed definitions of T cell-mediated rejection and tubulointerstitial inflammation as clinical trial endpoints in kidney transplantation by Seron, D, Rabant, M, Becker, JU, Roufosse, C, Bellini, MI, Böhmig, GA, Budde, K, Diekmann, F, Glotz, D, Hilbrands, L, Loupy, A, Oberbauer, R, Pengel, L, Schneeberger, S, Naesens, M
Published 2022Journal article -
3
Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation by Roufosse, C, Becker, JU, Rabant, M, Seron, D, Bellini, MI, Böhmig, GA, Budde, K, Diekmann, F, Glotz, D, Hilbrands, L, Loupy, A, Oberbauer, R, Pengel, L, Schneeberger, S, Naesens, M
Published 2022Journal article